Frontier IP sells part of stake in Exscientia
Group’s net proceeds of approximately $4 million following sale of 183,901 shares for an average price of $21.68 per ADS.
Read moreFrontier IP: anticipates first half results ahead of management expectations
The Group has enjoyed strong progress for the half year to 31 December 2021 and has started programme to sell part of its Exscientia holding. Read the trading update here.
Read moreCelerum launches first product using AI to improve logistics
Portfolio company Celerum has launched Truck Logistics System, its first commercial software based on novel technology inspired by nature. The product has also won its first customer.
Read moreTVG next-generation COVID-19 vaccine achieves significant milestone
Pre-clinical trial data for The Vaccine Group’s Covid-19 vaccine have demonstrated the potential for broad immunity against current and future variants of Sars-CoV-2.
Read more“For us, it is fantastic when you see a product getting deployed or out there.”
Chief Executive Neil Crabb discusses commercialisation, the role of science and technology in sustainability and much more in this interview with the British Embassy, Lisbon, at Web Summit 2021.
Read moreChief Executive Neil Crabb on our final results
Pre-tax profits up 145 per cent to £10.2 million and fair value of the equity portfolio increased by 64 per cent to £32 million: Neil discusses with Proactive.
Read moreBaroness Brown, chair of The Carbon Trust, joins Frontier IP board
Professor Dame Julia King, Baroness Brown of Cambridge, DBE FREng FRS, has been appointed as an independent Non-Executive Director.
Read moreFinal results: pre-tax profit up 145 per cent to £10.2 million
Exscientia makes significant contribution as profits and the fair value of our equity portfolio rise sharply. The numbers are significantly ahead of our expectations.
Read moreFrontier IP and the UN Sustainable Development Goals: our latest newsletter
Our latest newsletter sets out why we are aligning to the UN Sustainable Development Goals and features Nandi Proteins Chief Executive David Flower.
Read moreExscientia valued at $2.9 billion as it lists on Nasdaq
Frontier IP stake worth $34.4million after Exscientia raises $304.7 million in a public offer at $22 per American Depositary Share. The company raised a further $160 million through private placements with SoftBank and the Bill & Melinda Gates Foundation.
Read more